110 related articles for article (PubMed ID: 37492227)
1. Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.
Le Naour J; Montégut L; Pan Y; Scuderi SA; Cordier P; Joseph A; Sauvat A; Iebba V; Paillet J; Ferrere G; Brechard L; Mulot C; Dubourg G; Zitvogel L; Pol JG; Vacchelli E; Puig PL; Kroemer G
Oncoimmunology; 2023; 12(1):2237354. PubMed ID: 37492227
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.
Chiang SF; Huang KC; Chen WT; Chen TW; Ke TW; Chao KSC
Cancer Immunol Immunother; 2021 Oct; 70(10):2937-2950. PubMed ID: 33713152
[TBL] [Abstract][Full Text] [Related]
3. Knockout of formyl peptide receptor 1 reduces osteogenesis and bone healing.
Yang X; Xiao W; Le Q; Zhang Z; Wang W; Lee SH; Dighe A; Kerrigan JR; Cui Q
Life Sci; 2024 May; 344():122583. PubMed ID: 38508232
[TBL] [Abstract][Full Text] [Related]
4. Formyl peptide receptor 1 mitigates colon inflammation and maintains mucosal homeostasis through the inhibition of CREB-C/EBPβ-S100a8 signaling.
Li T; Zhou X; Zhang Q; Miao Q; Woodman OL; Chen Y; Qin C
Mucosal Immunol; 2024 Apr; ():. PubMed ID: 38614323
[TBL] [Abstract][Full Text] [Related]
5. Absence of formyl peptide receptor 1 causes endometriotic lesion regression in a mouse model of surgically-induced endometriosis.
Fusco R; D'amico R; Cordaro M; Gugliandolo E; Siracusa R; Peritore AF; Crupi R; Impellizzeri D; Cuzzocrea S; Di Paola R
Oncotarget; 2018 Jul; 9(59):31355-31366. PubMed ID: 30140375
[TBL] [Abstract][Full Text] [Related]
6.
Lei W; Cheng Y; Gao J; Liu X; Shao L; Kong Q; Zheng N; Ling Z; Hu W
Front Cell Infect Microbiol; 2023; 13():1224155. PubMed ID: 37492530
[TBL] [Abstract][Full Text] [Related]
7. Histamine antagonists promote cancer immunosurveillance.
Liu P; Kroemer G; Kepp O
Oncoimmunology; 2023; 12(1):2242211. PubMed ID: 37554311
[TBL] [Abstract][Full Text] [Related]
8. Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia.
Mimura K; Shimomura A; Watanabe K; Koda H; Nakayama K; Kitagawa D; Shimizu C
Oncol Lett; 2023 Aug; 26(2):357. PubMed ID: 37545613
[TBL] [Abstract][Full Text] [Related]
9. Machine learning discriminates P2X7-mediated intracellular calcium sparks in human-induced pluripotent stem cell-derived neural stem cells.
Hanafusa Y; Shiraishi A; Hattori F
Sci Rep; 2023 Aug; 13(1):12673. PubMed ID: 37542080
[TBL] [Abstract][Full Text] [Related]
10. Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.
Song EM; Na SY; Hong SN; Ng SC; Hisamatsu T; Ye BD
Intest Res; 2023 Jul; 21(3):339-352. PubMed ID: 37533265
[TBL] [Abstract][Full Text] [Related]
11. Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer.
Sugimura N; Kubota E; Mori Y; Aoyama M; Tanaka M; Shimura T; Tanida S; Johnston RN; Kataoka H
Cancer Immunol Immunother; 2023 Nov; 72(11):3593-3608. PubMed ID: 37526659
[TBL] [Abstract][Full Text] [Related]
12. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
13. Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment.
Waldstein S; Spengler M; Pinchuk IV; Yee NS
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511727
[TBL] [Abstract][Full Text] [Related]
14. Unveiling and harnessing the human gut microbiome in the rising burden of non-communicable diseases during urbanization.
Huang Z; Li Y; Park H; Ho M; Bhardwaj K; Sugimura N; Lee HW; Meng H; Ebert MP; Chao K; Burgermeister E; Bhatt AP; Shetty SA; Li K; Wen W; Zuo T
Gut Microbes; 2023; 15(1):2237645. PubMed ID: 37498052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis.
Paridaens K; Fullarton JR; Travis SPL
JGH Open; 2023 Jul; 7(7):516-519. PubMed ID: 37496812
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation.
Tolou-Ghamari Z
Cardiovasc Hematol Agents Med Chem; 2023 Jul; ():. PubMed ID: 37496131
[TBL] [Abstract][Full Text] [Related]
17. Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab: Different Clinical Course in the Colon and Gastroduodenal Lesions.
Hayashi T; Terashima T; Nishitani M; Orita N; Miyazawa M; Seki A; Nakagawa H; Nio K; Iida N; Yamada S; Takatori H; Shimakami T; Yamashita T
Intern Med; 2024 Apr; 63(7):929-935. PubMed ID: 37495533
[TBL] [Abstract][Full Text] [Related]
18. Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
Gomes L; Marques MA; Ferreira PG
J Bras Pneumol; 2023 Jul; 49(3):e20220467. PubMed ID: 37493790
[No Abstract] [Full Text] [Related]
19. Effects of Cefixime on Immune Functions and Inflammatory Factors in Children with Urinary Tract Infection and Targeted Nursing Strategies.
Han J; Luo D; Han X
Arch Esp Urol; 2023 Jul; 76(5):313-318. PubMed ID: 37545149
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
Vidigal AC; de Lucena DD; Beyerstedt S; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2023; 19(7):405-427. PubMed ID: 37542452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
